Creative Planning Biogen Inc. Transaction History

Creative Planning

$101 Billion
Q3 2024

A detailed history of Creative Planning transactions in Biogen Inc. stock. As of the latest transaction made, Creative Planning holds 13,774 shares of BIIB stock, worth $2.02 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

13,774

Previous 18,274 24.63%

Holding current value

$2.02 Million

Previous $4.24 Million 36.99%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 11, 2024	SELL	$189.07 - $236.8 $850,815 - $1.07 Million	-4,500 Reduced 24.63%	13,774 $2.67 Million
Q2 2024 Aug 15, 2024	BUY	$190.52 - $236.72 $852,195 - $1.06 Million	4,473 Added 32.41%	18,274 $4.24 Million
Q1 2024 May 10, 2024	BUY	$212.02 - $267.71 $275,201 - $347,487	1,298 Added 10.38%	13,801 $2.98 Million
Q4 2023 Feb 14, 2024	SELL	$222.59 - $267.94 $170,726 - $205,509	-767 Reduced 5.78%	12,503 $3.24 Million
Q3 2023 Nov 16, 2023	SELL	$253.3 - $285.89 $406,293 - $458,567	-1,604 Reduced 10.78%	13,270 $3.41 Million
Q2 2023 Jul 21, 2023	BUY	$275.25 - $318.06 $347,090 - $401,073	1,261 Added 9.26%	14,874 $4.24 Million
Q1 2023 May 15, 2023	BUY	$256.56 - $292.34 $27,708 - $31,572	108 Added 0.8%	13,613 $3.78 Million
Q4 2022 Feb 10, 2023	BUY	$252.44 - $306.72 $477,868 - $580,620	1,893 Added 16.3%	13,505 $3.74 Million
Q3 2022 Nov 03, 2022	BUY	$194.69 - $268.46 $82,743 - $114,095	425 Added 3.8%	11,612 $3.1 Million
Q2 2022 Aug 15, 2022	SELL	$187.54 - $223.02 $282,060 - $335,422	-1,504 Reduced 11.85%	11,187 $2.28 Million
Q1 2022 May 16, 2022	SELL	$193.77 - $244.14 $57,549 - $72,509	-297 Reduced 2.29%	12,691 $2.67 Million
Q4 2021 Feb 11, 2022	SELL	$223.92 - $287.77 $148,011 - $190,215	-661 Reduced 4.84%	12,988 $3.12 Million
Q3 2021 Nov 10, 2021	BUY	$282.99 - $369.05 $185,641 - $242,096	656 Added 5.05%	13,649 $3.86 Million
Q2 2021 Aug 04, 2021	SELL	$259.0 - $414.71 $3.26 Million - $5.22 Million	-12,580 Reduced 49.19%	12,993 $4.5 Million
Q1 2021 Apr 30, 2021	SELL	$242.95 - $284.63 $43,002 - $50,379	-177 Reduced 0.69%	25,573 $7.15 Million
Q4 2020 Jan 29, 2021	SELL	$236.26 - $355.63 $137,739 - $207,332	-583 Reduced 2.21%	25,750 $6.31 Million
Q3 2020 Nov 05, 2020	BUY	$264.77 - $305.71 $170,776 - $197,182	645 Added 2.51%	26,333 $7.47 Million
Q2 2020 Jul 23, 2020	SELL	$258.66 - $342.55 $150,540 - $199,364	-582 Reduced 2.22%	25,688 $6.87 Million
Q1 2020 May 05, 2020	BUY	$268.85 - $341.04 $56,996 - $72,300	212 Added 0.81%	26,270 $8.31 Million
Q4 2019 Jan 30, 2020	SELL	$220.06 - $304.07 $18,705 - $25,845	-85 Reduced 0.33%	26,058 $7.73 Million
Q3 2019 Nov 01, 2019	SELL	$217.44 - $243.88 $298,327 - $334,603	-1,372 Reduced 4.99%	26,143 $6.09 Million
Q2 2019 Jul 26, 2019	SELL	$219.29 - $241.72 $299,988 - $330,672	-1,368 Reduced 4.74%	27,515 $6.44 Million
Q1 2019 Apr 24, 2019	BUY	$216.71 - $338.96 $404,597 - $632,838	1,867 Added 6.91%	28,883 $6.83 Million
Q4 2018 Feb 01, 2019	SELL	$278.5 - $352.75 $444,486 - $562,989	-1,596 Reduced 5.58%	27,016 $8.13 Million
Q3 2018 Oct 25, 2018	BUY	$293.51 - $383.83 $244,787 - $320,114	834 Added 3.0%	28,612 $10.1 Million
Q2 2018 Jul 20, 2018	SELL	$257.52 - $306.91 $39,915 - $47,571	-155 Reduced 0.55%	27,778 $8.06 Million
Q1 2018 Apr 18, 2018	SELL	$260.13 - $367.91 $90,525 - $128,032	-348 Reduced 1.23%	27,933 $7.65 Million
Q4 2017 Jan 17, 2018	BUY	$307.64 - $344.58 $619,279 - $693,639	2,013 Added 7.66%	28,281 $9.01 Million
Q3 2017 Oct 17, 2017	BUY	$281.15 - $329.69 $7.39 Million - $8.66 Million	26,268	26,268 $8.23 Million

Others Institutions Holding BIIB

# of Institutions

1,037

Shares Held

126M

Call Options Held

1.13M

Put Options Held

1.43M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $21.1B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.

Account

Creative Planning Biogen Inc. Transaction History